User:Taras81/sandbox

National BioService  (Russian: «Национальный БиоСервис») is the first fully compliant biospecimen CRO operating in Russia. The company has a network of over 125 clinical centers in 30 cities across the country together capable of completing biospecimens collection projects for the purposes of biomedical research and development. All clinics are formally contracted and managed by NBS. NBS has also established 6 laboratories in five regions of Russia: Moscow, Saint-Petersburg, Nizhniy Novgorod, Samara and Sochi. Each is equipped and staffed to allow for consistent processing and characterization of biospecimens collected in those respective regions. The level of processing and characterization varies from relatively simple activities to more high-tech work. These include cell-sorting and genetic characterization by PCR and NGS based technologies in licensed clinical diagnostic labs. In addition to prospective collection capabilities, NBS has created a biobank representing disease areas, such as hematology, rheumatology, oncology, neurology, gastroenterology, etc.

History
The company was founded in 2013 in Saint-Petersburg by a team of Russian scientists with extensive international experience in biomedical R&D. '''
 * In 2015, NBS established its first regional branch in Nizhniy Novgorod (Volga region)
 * In 2016, National BioService became the first in Russia institutional member of The International Society for Biological and Environmental Repositories (ISBER).
 * In 2017, the Moscow branch of NBS started to operate in Skolkovo Technopark.
 * In 2018, the molecular genetic laboratory was created in Saint-Petersburg to support genetic characterization of biospecimens and clinical testing of patients with oncological conditions.
 * In 2019, NBS launched two regional branches – one in Samara (Volga region) and another in Sochi (South of Russia).
 * By the middle of 2020, the collaborative network in Russia includes over 125 medical centers and 6 regional laboratories and biobanks. In addition to providing services to biopharmaceutical and diagnostic companies, NBS launched its own research projects, such as LUCARD study

Membership
''' As the first in Russia institutional member of ISBER, NBS supports the development of the biobanking network in Russia, in line with ISBER’s recommendations and guidelines. In particular, NBS produced translation and released Russian edition of ISBER Best Practices: Recommendations for Repositories, Fourth Edition (in 2018) and then its addendum (ADDENDUM 1: Liquid Nitrogen-Based Cryogenic Storage of Specimens; in 2020).

NBS is a co-founder and current member of NASBIO — Russian National Association of Biobanks and biobanking specialists. NASBIO was established in 2018 to promote and support the development of biobanking in Russia. The Aim of NASBIO is to unite the efforts of experts in the field of biobanking in order to develop a network of Biobanks in Russia, to provide specialist and educational services and assist in the development and implementation of scientific projects utilizing the assets and infrastructure of Biobanks.

'''

Ethics and personal data protection
'''

NBS operates in compliance with local and international requirements and recommendations related to ethics and Personal Data protection. GDPR principles are implemented and strictly adhered to in daily activities of NBS. Biospecimens donor’s data in the biobank’s database are pseudonymized or anonymized. Personal Data is collected, processed and transferred in accordance with local Data Protection Laws. Appropriate technical and organizational measures are taken to protect Personal Data against accidental or unlawful destruction, loss or damage, alteration and unauthorized access or disclosure.

Informed Consent Forms (ICF) used for biospecimens collection are approved by Institutional Review Boards (IRB) or an Independent Ethics Committee. '''

Biospecimens collections
''' Online real-time biobanking collections are accessed and organized via the NBS web site (NBS Platform). The scientists can explore inventories of materials instantly while being able to share them with other laboratories.

'''

Patents
'''

The company owns 2 patents on recipient block for tissue macroarray production. Thus, National BioService is the only developer and manufacturer of tissue microarrays (TMA) in Russia.

'''

Opinion
''' Dr. Zisis Kozlakidis, Past President of ISBER, Head of Laboratory services and biobanking IARC (WHO) was dedicated to the development of the Russian biobanking environment. “It’s really exciting to see this initiative taking shape” he said, noting that Russia is placing itself amongst the world leaders in the expansion of biobanks. As part of an effort to adopt the best practices in biobanking, an official Russian translation of ISBER Best Practices Fourth Edition was published, both in hardback form and electronically, in 2018 with help from NBS. This publication aims to help Russian specialists become familiar with and operate within harmonized international practices and support the potential development of national standards.

'''

Funding
''' NBS is a fully commercial biobank.

'''

Research
''' NBS is involved in many collaborative research projects with industrial and academic partners. Recently the company has expanded its activities by initiating its own research projects, such as:

LUCARD (Lung Cancer Residential Disease Study): the first in Russia study to assess Minimal Residual Disease in operable non-small cell lung cancer.

OncoBRCA : The aim of the project is to share knowledge about the genetic basis of breast, ovarian and other cancer types by combining information about BRCA 1/2 variants and related clinical data.